Applications Are Open: 2026 Power Player Awards
Nominate yourself (or someone who deserves it).
In our monthly FitGrid x ATN benchmarking data dive, we tackle what the cycling modality needs to do to stay competitive.
Gym visits dipped very slightly in Q2 2026, marking the industry's first year-over-year slowdown since the post-pandemic boom. But a June rebound hints at strong momentum heading into the second half of the year
More than 25% of GLP-1 users in the U.K. reported increasing fitness spending after starting treatment. Those results are promising, but other data shows it's far from a given that weight-loss drugs will prove to be a net benefit for the industry
A 30-year study indicates that weekly strength training for 90 to 120 minutes has serious benefits for lowering risk of death, with no further benefit found above that duration
New data spotlights a "readiness gap": personal trainers have the certifications, but they're not getting the business coaching they need.
A new Myzone report shows that gym members across age groups are spending more time working out in lower-to-moderate intensity zones, which it calls "habit and longevity" training.
Fitbit data from 750 adults found that daily movement and exercise levels declined after people started taking GLP-1 weight-loss drugs.
An ABC Fitness report indicates that gym joins declined 9% and studio joins fell 5% YoY as new members, who increasingly skew younger, seek out communal fitness opportunities.
Zenoti's new fitness consumer survey reveals a chasm between the engagement members expect from their gyms, and what they’re actually receiving.
The study reveals numerous benefits of an integrated care model that combines weight-loss drugs with exercise, especially strength training.
Sign Up to Our Newsletter
